Physician profile
Jayanth Bolaram
NPI 1336251016
$16,544.05
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,769 · 2020: $4,688 · 2021: $2,909 · 2022: $3,964 · 2023: $57.77 · 2024: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $8,922.47 | 2019-2020 | |
| Abbvie INC. | $6,264.35 | 2021-2022 | |
| Alkermes, INC. | $390.81 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $294.81 | 2020-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $204.68 | 2021-2024 | Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $173.42 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $99.62 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $62.22 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $37.53 | 2021 | |
| Jazz Pharmaceuticals INC. | $34.47 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $18.03 | 2023 | Austedo Xr |
| Eisai INC. | $14.94 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.44 | 2020 | |
| Merck Sharp & Dohme LLC | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayanth Bolaram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.